28 September 2021>: Original Paper
Is Continuing Anticoagulation or Antiplatelet Therapy Safe Prior to Kidney Transplantation?
Jose C. Alonso-Escalante ABCDEF* , Lorenzo Machado ABDEF , Kiumars R. Tabar ABDE , Rachell Tindall DE , Ngoc Thai ADE , Tadahiro Uemura ACDEFDOI: 10.12659/AOT.931648
Ann Transplant 2021; 26:e931648
Table 3 Perioperative bleeding complications, prolonged length of stay, and 3-month and 6-month outcomes.
CTL | WARF | ASA/CLOP | p Value | |
---|---|---|---|---|
3-Month graft exploration | 3% | 0% | 3% | 0.69 |
6-Month graft exploration | 1% | 4% | 0% | 0.12 |
Perioperative blood transfusion | 4% | 4% | 13% | 0.13 |
3-Month outcomes | ||||
Prolonged LOS (>7 days) | 24% | 26% | 44% | 0.08 |
Hemodialysis | 5% | 13% | 6% | 0.71 |
Creatinine (mg/dL) | 1.6 | 1.5 | 1.6 | 0.49 |
Rejection | 9% | 4% | 6% | 0.32 |
6-month outcomes | ||||
Prolonged LOS (>7 days) | 24% | 26% | 44% | 0.08 |
Hemodialysis | 5% | 13% | 6% | 0.71 |
Creatinine (mg/dL) | 1.6 | 1.5 | 1.6 | 0.49 |
Rejection | 9% | 4% | 6% | 0.32 |